Logo image
Back
S2007 The Impact of Long-Term Aspirin Use on Outcomes Among Hospitalized Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Abstract   Peer reviewed

S2007 The Impact of Long-Term Aspirin Use on Outcomes Among Hospitalized Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Muhamad Oum, Humzah Iqbal, Rakahn Haddadin, Jalal Samhoun, Fatimah Aftab, Haroon Iqbal, Hasib Haidary, Yahya Alsawaf, Mhd Kutaiba Albuni, Bisher Sawaf, …
The American journal of gastroenterology, Vol.119(10S), pp.S1435-S1435
10/2024
DOI: 10.14309/01.ajg.0001037396.08463.49

View Online

Abstract

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease in Western countries, affecting over 30% of US adults. This condition is often progressive, with up to one-third of patients developing steatohepatitis and fibrosis, potentially leading to cirrhosis, hepatocellular carcinoma, and ultimately, mortality. Recent studies have highlighted that aspirin reduces hepatic fat content, suggesting a preventive role against the progression of fibrosis and liver cancer. Inspired by these findings, we examined data from the Nationwide Inpatient Sample (NIS) 2020 to assess the impact of long-term aspirin use on clinical outcomes in MASLD patients. Methods: Patients with MASLD based on International Classification of Diseases-10th Revision (ICD-10) codes were identified using the Nationwide Inpatient Sample (NIS) 2020. Patients were stratified based on long-term aspirin use. Outcomes assessed included in-hospital mortality, shock, sepsis, acute kidney injury (AKI), intensive care unit (ICU) admission, peritonitis, length of stay (LOS), and total hospitalization charges. The relationship between variables of interest and outcomes was assessed using multivariate logistic regression after adjusting for confounding factors. Results: A total of 463,999 MASLD patients were included in the final analysis. Of these, 54,288 patients (11.7%) were on long-term aspirin use. On multivariate regression analysis, long-term aspirin use was associated with decreased odds of in-hospital mortality (aOR 0.46, P < 0.001), shock (aOR 0.57, P < 0.001), sepsis (aOR 0.70, P < 0.001), AKI (aOR 0.79, P < 0.001), ICU admission (aOR 0.59, P < 0.001), and peritonitis (aOR 0.3, P < 0.001). Long-term aspirin use was also associated with shorter LOS (4.7 days vs 5.3 days) and lower total hospitalization charges ($58,924 vs $72,850). Conclusion: In our study, 11.7% of MASLD patients were on long-term aspirin use. We found that long-term aspirin use was associated with decreased odds of in-hospital mortality, shock, sepsis, AKI, ICU admission, and peritonitis. Additionally, patients on long-term aspirin use had shorter LOS and lower total hospitalization charges. MASLD patients might benefit from long-term aspirin use, as recent studies have shown that it also lowers fat content and might slow the progression to cirrhosis and cancer (Figure 1).

Details

Metrics

1 Record Views
Logo image